Gilpin Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-23
Closed -$723 – 1437
2026
Q2
$723 Hold
23
– – ﹤0.01% 569
2026
Q1
$570 Buy
23
+15
+188% +$357 ﹤0.01% 575
2025
Q4
$187 Buy
+8
New +$178 ﹤0.01% 676

Other funds holding CPRX

Gilpin Wealth Management's CPRX Position: Q3 2026 in Review

Gilpin Wealth Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 23 shares — an estimated $723 sold.

Gilpin Wealth Management first reported a position in CPRX in Q4 2025 and held it in 3 quarters. The position peaked at $723 in Q2 2026. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

  • Gilpin Wealth Management reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • Gilpin Wealth Management sold 23 Catalyst Pharmaceutical shares in Q3 2026, an estimated $723.
  • Gilpin Wealth Management first reported a position in Catalyst Pharmaceutical in Q4 2025 and held it in 3 quarters.
  • Gilpin Wealth Management's Catalyst Pharmaceutical position peaked at $723 in Q2 2026.
  • 2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.